Rossari Biotech Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/q2x5n4b0d7oja33eojzlofvj.pdf

Key Takeaways


Volume vs Price: The Quarter's Real Story

Chari: "The supply chain has stabilized, but the prices have not stabilized yet. There is still huge volatility in the prices."

Subsidiary Integration & Synergy Delivery

Chari: "...all the acquisitions have done exceedingly well. We have been able to integrate very well, we have had no surprises in all the acquisitions. Unitop of course, is outstanding. The amount of growth which has happened both on profitability and on volume and value growth we are happy."

New Product Pipeline & R&D Commercialisation


Margin Resilience & Cost Structure

Chari: "We have been brave, we have been able to pass on price hikes to the customers. ... when the price increased substantially, we did not increase the amount of margin, but we maintained our margins. And so that is why we are seeing a gradual improvement in margins across Rossari."

Demand Environment & End-Market Health


Guidance & Commitments

CommitmentSpecificsTimeline
H2 FY23 top lineReplicate H1 with 5-10% growthH2 FY23
FY23 full-year revenue₹1,800 crore to ₹2,000 croreFY23
FY23 EBITDA margin12% to 14% rangeFY23
Gross margin recoveryReturn to 30-35% consolidated2-3 years
Gross margin near-termStay at current 26-27%Next few quarters
EBITDA margin objectiveReturn to 14-15%Normalised operating environment (no date)
EBITDA margin longer-termReturn to ~15%Longer period (no date)
Working capital cycle70-75 days consolidatedInternal target (no date)
IND AS interest chargeContinue as notional, non-cash chargeUntil 100% subsidiary acquisition completed
Inventory postureRemain conservative, no long positionsThis quarter
Silicon polymers for agroApprovals to culminate in businessNext year

Key Metrics

MetricQ2 FY23
Consolidated revenue₹425.4 cr, down 2% QoQ from ₹434.7 cr
Standalone revenue₹240.9 cr, up 3% QoQ from ₹233.7 cr
HPPC revenue₹303.9 cr, 71% of total revenue
TSC revenue₹91.4 cr, 22% of total revenue
AHN revenue₹30.2 cr, 7% of total revenue
Consolidated EBITDA₹56.6 cr, down 2% QoQ from ₹57.7 cr
Consolidated PAT₹23.9 cr, down 17% QoQ from ₹28.7 cr
H1 FY23 EBITDA margin13.3%, stable YoY
H1 FY23 gross margin improvement357 bps YoY
HPPC volume growth7%-8% QoQ, consolidated
Unitop and Tristar combined H1 top-line growth40%-45%, vs pre-acquisition H1
Unitop and Tristar combined YoY top-line growth60%-70%, post one year of acquisition
Capacity utilization50%-55%, across all entities, similar to Q1
FY23 top-line outlook₹1,800 cr to ₹2,000 cr
FY23 EBITDA margin outlook12% to 14%